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 ABSTRACT 
Amavata is a very common disorder affecting a much larger population. The disease 
closely resembles Rheumatoid Arthritis on the basis of clinical manifestations. In the 
present study, we have considered Rheumatoid Arthritis parallel to Amavata and 
studied the effect of Rasona Pinda, a traditional Ayurvedic drug. 40 patients of 
Amavata were selected and randomly divided into two groups A and B. Group A was 
trial group and Group B was control group. Group A received Rasona Pinda and group 
B as control group received Indomethacin orally, duration of treatment for both the 
groups was 45 days with a follow up on every 15th day. The drug was selected as it is 
described in Chakradatta Amavatadhikara and also owing to its properties. Results 
were assessed according to a specially prepared grading system for pain, swelling, 
stiffness, tenderness, general functional capacity, walking time, grip power, pressing 
power, etc and changes observed in laboratory profile. Significant improvement was 
seen in symptoms in group A, and on comparing the results in the two groups it was 
found that the difference was highly significant with improvement in almost all the 
symptoms in group A. and also, it was found that the drug was free of side effects and 
showed improvement in the general health of the patient. The study suggests that 
Rasona Pinda can be a reliable alternative in the management of Amavata.  
KEYWORDS: Amavata, Indomethacin, Rasona Pinda, Rheumatoid Arthritis. 
INTRODUCTION
Amavata is one of the commonest 
disorders caused by the impairment of 
Agni(digestive power), formation of Ama 
(undigested elements in body) and vitiation of 
Vata[1] which initially creates difficulty in 
performing daily works which goes on increasing 
and further leads to deterioration in the form of 
physical deformities as well as mental frustration. 
Amavata on the basis of clinical 
appearance can be taken parallel to Rheumatoid 
Arthritis. It is a commonest autoimmune 
inflammatory diseases of chronic multiple organ 
systems and of unknown etiology. Characteristic 
feature is persistent inflammatory synovitis, 
usually involving peripheral joints in a symmetric 
distribution. If left untreated, leads to joint 
destruction, which is responsible for the 
deformity and disability seen in this disease. 
 Allopathic drugs are insufficient for 
complete eradication of disease. Moreover, 
treatment according to modern science is 
expensive, prolonged, creates many side effects 
and affects the quality of individuals to larger 
extent. Rheumatoid Arthritis is the 42nd leading 
cause of increased no of YLDs (Years lived with 
Disability) at global level2. Its wide prevalence, 
chronicity, morbidity, crippling nature & lack of 
effective drugs attract to search for suitable 
remedy of disease Amavata. 
 Thus the study was designed to find out a 
drug or a management schedule that is effective in 
the management of Amavata vis-à-vis Rheumatoid 
Arthritis, is easy to be administered, is free of side 
effects and takes lesser duration in decreasing the 
disease progression and thus avoids landing into 
complications. 
The formulation under trial in this study, 
Rasona Pinda is described in the Ayurvedic Text in 
Chakradatta Amavataadhikara. For comparison, 
Indomethacin is taken as standard drug and is 
administered to the control group.  
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MATERIAL AND METHODS 
Preparation of drug: The drug was 
prepared according to method of preparation as 
described in Chakradatta[3]. The quantity of 
ingredients in metric measurements was decided 
according to Ayurvedic Formulary of India. 
 
Table 1: Ingredients of Rasona Pinda 
S.No. Name Botanical Name Quantity 
1. Rasona Allium sativum L. 100 Pala (4.8kg) 
2. Tila Sesamum indicum L. 1 Kudava (192gm) 
3. Hingu Ferula narthex Boiss. 1 Pala (48gm) 
4. Trikatu Zingiber officinale Rosc. 
Piper nigrum L. 
Piper longum L. 
1 Pala (48gm) 
5. Ksharadvaya - 1 Pala (48gm) 
6. Panchalavana - 1 Pala (48gm) 
7. Shatapushpa Anethum sowa Kurz. 1 Pala (48gm) 
8. Kushtha Saussurea lappa C.B.CL. 1 Pala (48gm) 
9. Pippalimula Piper longum L. 1 Pala (48gm) 
10. Chitraka Plumbago zeylanica L. 1 Pala (48gm) 
11. Ajamoda Apium leptophyllum F.Muell. 
Ex.Benth. 
1 Pala (48gm) 
12. Yawani Trachyspermum ammi (L.) 
Sprague 
1 Pala (48gm) 
13. Dhanyaka Coriandrum sativum L. 1 Pala (48gm) 
14. Tilataila Sesamum indicum L. oil 1 Manika (384 ml) 
15. Kanji  sour gruel ½ Prastha (384 ml) 
Patient selection: 40 patients of Amavata were 
registered from Kayachikitsa OPD, Sir Sundarlal 
Hospital, BHU, Varanasi. The case selection was 
random regardless of age, sex, occupation and 
socio-economic conditions. Both acute and chronic 
phase of Amavata patients were taken for the 
study, following the 1987 revised criteria by 
American college of Rheumatology for diagnosis of 
Rheumatoid arthritis[4] and the clinical features of 
Amavata described in Madhava Nidana.  
Table 2: The 1987 Revised Criteria by American College of Rheumatology for Diagnosis of 
Rheumatoid Arthritis 
1 Morning stiffness 
 
Morning stiffness in and around the joints, lasting at least 1 hour before 
maximal improvement. At least 3 joints. 
2 Arthritis of 3 or more 
joint areas 
 
Areas simultaneously have had soft tissue swelling or fluid (not bony 
overgrowth alone) observed by a physician. The 14 possible areas are 
right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints. 
3 Arthritis of hand 
joints 
At least 1 area swollen (as defined above) in a wrist, MCP or PIP joint. 
4 Symmetric arthritis 
 
Simultaneous involvement of the same joint areas [as defined in (2)]on 
both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs is 
acceptable without absolute symmetry). 
5 Rheumatoid nodules 
 
Subcutaneous nodules, over bony prominences, or extensor in juxta 
articular regions, observed by a physician. 
6 Serum rheumatoid 
factor 
 
Demonstration of abnormal amounts of serum rheumatoid factor or any 
method for which the result has been positive in <5% of normal control 
subjects. 
7 Radiographic changes 
 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include erosions 
or unequivocal bony decalcification localized in or most marked adjacent 
to the involved joints (osteoarthritis changes alone do not qualify). 
*for classification purposes, a patient shall be said to have rheumatoid arthritis is he/she has satisfied 
at least four of these seven criteria. Criteria 1 through 4 must have been present for at least six weeks. 
The selected patients were subjected to 
clinical examination laboratory investigations 
after registration and after completion of 
treatment. 
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INCLUSION CRITERIA 
1. The patients of Rheumatoid Arthritis with 
mild, moderate and severe degree of 
presentation were included in the present 
study. 
2. Both cases of Seropositive and Seronegative 
were included in present study.  
3. The patients included will be within age 
group of 15- 65 yrs. 
EXCLUSION CRITERIA 
1.  The patients having severe degree of 
deformities. 
2.  The patients having severe ankylosed joints. 
3.  The patients with major complications were 
also excluded 
4.  The patients on corticosteroid therapy. 
5.  Patient of rheumatic arthritis, septic 
arthritis osteoarthritis and gouty arthritis or 
any other type of arthritis.  
ASSESSMENT OF DISEASE 
A. Assessment of functional status 
1. Walking time: The walking time taken by the 
patients for a fixed distance was observed 
and recorded to know the time consumed to 
cross the fixed distance. This test provides 
functional status of hip, knee, ankle and 
smaller joints of the lower limbs. In the 
present study a distance of 25 ft was fixed for 
the purpose, and grading was given. 
2. Grip power and pressing power: The 
functional status of wrist joints, 
metacarpophalangeal joints and 
interphalangeal joints was assessed by 
measuring of pressing power and grip power. 
For this test (Grip power), patients were 
asked to grip the inflated cuff of a 
sphygmomanometer by both palms and 
fingers separately and the rise of manometer 
readings was recorded in mmHg of mercury 
at the time of registration and follow ups of 
the patients of Amavata. For measuring the 
pressing power the cuff of 
sphygmomanometer was inflated at the basal 
value and was placed on the table. The 
patient sitting on front of the table on a chair 
was told to press the inflated cuff by both 
hands separately. While pressing the cuff 
pressure should be applied from all the 
involved joints of upper limbs and the extent 
to which the patient can press the cuff is 
observed in terms of the rise in mercury 
column in mm of Hg. This is done at the time 
of registration and follow ups. In both the 
tests the cuff of sphygmomanometer was 
inflated up to basal value of 30 mm of Hg. 
Grading was done. 
B. Clinical assessment 
Clinical assessment of the disease, its 
severity, extent and grades of inflammation were 
objectively done in terms of pain, swelling, 
tenderness, deformity, general function capacity 
and stiffness of the joints. The relative extent of all 
these criteria was recorded according to the rating 
scales in each patient at the initial stage and at 
subsequent follow ups. These are measured by 
simple count of clinically active joints. 
Table 3: Grading System Used for Assessment of Disease 
WALKING TIME INDEX 
0 : 15 - 20 sec 
1 :  21- 30 sec 
2 :  31- 40 sec 
3 :  > 40 sec 
GRIP POWER AND PRESSING POWER 
0 :  200 mmHg 
1 :  198 – 120 mmHg 
2 :  118 – 70 mmHg 
3 :  <70 mmHg 
PAIN 
0 :  No pain 
1 :  Pain complaints but tolerable 
2 : Pain complaints difficult to tolerate and taking analgesic once a day 
3 : Intolerable pain and taking analgesics two times a day 
4 : Intolerable pain and taking analgesics more than two times in a day 
SWELLING 
0 : No swelling 
1 : Feeling of swelling + Heaviness 
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2 :  Apparent swelling 
3 : Huge (Synovial effusion) swelling 
STIFFNESS 
0 :  No stiffness 
1 : 20% limitation of normal range of mobility 
2 : 50% limitation of mobility 
3 : 75% or more reduction of normal range of movement 
GENERAL FUNCTIONAL CAPACITY 
0 : Complete ability to carry on all routine duties 
1 : Frequent normal activity despite slight difficulty in joint movement 
2 : Few activities are persisting but patient can take care of him or herself 
3 : Few activities are persisting patient requires an attendant to take care of him/herself 
4 : Patient is totally bed ridden  
TENDERNESS 
0 : No tenderness  
1 : Mild tenderness 
2 : Moderate tenderness 
3 : Severe tenderness 
C. Laboratory profile 
For the purpose of diagnosis of a disease 
its assessment, severity, clinical improvement and 
to assess the possible side effects, certain routine 
and specific investigations were performed in 
every patients viz. 
1. Hematological investigations: Total 
leucocytes count, Differential leucocytes 
count, Hemoglobin, Erythrocyte 
Sedimentation Rate 
2. Biochemical: C-Reactive Protein (C-RP titre), 
Rheumatoid factor (RA factor) 
TREATMENT SCHEDULE 
The patients from group A were given 
Rasona Pinda 1g TDS orally with lukewarm water 
and patients from group B(control group) were 
given Indomethacin 75 mg OD orally. For both 
groups, the treatment was continued for 45 days 
and follow up was done on every 15th day, that is 
on 15th, 31st and 45th day. 
STATISTICAL ANALYSIS 
The result was assessed on the basis of 
relief in symptoms and serological tests.  
 Comparison between two groups (Intergroup 
Comparison) was done using Mann Whitney 
test. 
 Intra group comparison was done using 
Friedman’s test. 
 Comparison of Mean was done by one way 
Annova test, Wilcoxan’s signed rank test, 
paired t test and Mann Whitney test as per 
requirement. 
The data was assessed for its statistical 
significance. 
OBSERVATION AND RESULTS 
Following observations and results were obtained. 
 In the present study, total 40 patients were 
registered out of which 35 patients 
completed the treatment. (GroupA-18pts, 
GroupB-17pts.) 
 Maximum patients were married & females 
of age group between 36-45 years which 
were housewives. Maximum patients were of 
middle class. 
 Maximum patients were of Urban origin 
showing life style modification causing more 
no. of diseased patient in urban areas. 
 Maximum patients dietary habit was of 
mixed type. Maximum patients were having 
Kapha-Vata Prakriti with Avara Agnibala and 
altered bowel habits. 
  Maximum number of patients had Negative 
family history with chronicity less than 2 
years. 
 Maximum patients were R.A. positive. 
Though the presence of Rheumatoid factor 
does not establish the diagnosis of 
Rheumatoid arthritis. But it can be of 
prognostic importance, because patient with 
high titer have more severe and progressive 
disease with extra articular manifestations. 
 Pain, swelling, tenderness and stiffness were 
found significantly reduced in Group A. 
Appetite was increased significantly in Group 
A, in comparison to Group B, rather it was 
deranged in some of the patients in Group B. 
EFFECT OF THERAPY 
On the basis of symptoms and 
examinations on third follow up, the effect of 
therapy was assessed. Maximum effect with 
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significant relief was observed in- tenderness 
(50% with no tenderness) and General functional 
capacity (50% with normal GFC). Significant 
reduction in severity of symptoms was found in 
pain (55.6% with mild pain), swelling (50% with 
mild swelling), stiffness (66.7% with mild 
stiffness) at the end of therapy. Improvement was 
observed on examination as walking time of 
61.1% patients was decreased, grip power- right 
hand (44.4% Grade1), left hand (33.3% each in 
Grade 1 and 2) and press power-right hand 
(44.4% Grade), left hand (33.3% each in Grade 1 
and 2) at the third follow up. 
Table 4: Effect of Therapy on Tenderness
Group Grading Tenderness Intragroup 
comparison 
(Friedman’s test) 
BT Follow up 1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 1 5.6 1 5.6 6 33.3 9 50 2 = 41.797 
p = 0.000 
(p<0.001 =H.S.) 
1 5 27.8 9 50 10 55.6 9 50 
2 7 38.9 6 33.3 2 33.3 0 0 
3 5 27.8 2 11.1 0 0 0 0 
 
B 
(n=17) 
0 2 11.8 2 11.8 2 11.8 2 11.8 2 = 19.054 
p = 0.000 
(p<0.01 = H.S.) 
1 3 17.6 2 11.8 5 29.4 7 41.2 
2 8 47.1 9 52.9 10 58.8 8 47.1 
3 4 23.5 4 23.5 0 0 0 0 
Pairwise 
group 
comparison  
 
A Vs B 
z = 0.465 
p = 0.642 
(p>0.05=N.S.) 
z = 2.149 
p = 0.032 
(p<0.05=S.) 
z = 3.788 
p = 0.000 
(p<0.001=H.S.) 
z = 4.312 
p = 0.000 
(p<0.001=H.S.) 
 
Table 5: Effect of Therapy on General Functional Capacity 
Group Grading General Functional Capacity Intragroup 
comparison  BT Follow up 1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 1 5.6 1 5.6 3 16.7 9 50 2 = 34.570 
p = 0.000 
(p<0.001 =H.S.) 
1 5 27.8 7 38.9 10 55.6 8 44.4 
2 12 66.7 10 55.6 5 27.8 1 5.6 
3 0 0 0 0 0 0 0 0 
 
B 
(n=17) 
0 1 5.9 1 5.9 1 5.9 1 5.9 2 = 1.737 
p = 0.629 
(p>0.05 = N.S.) 
1 5  29.4 5 29.4 4 23.5 4 23.5 
2 11 64.7 11 64.7 11 64.7 12 70.6 
3 0 0 0 0 1 5.9 0 0 
Pairwise group 
comparison  
 
A VsB 
z = 1.046 
p>0.05=N.S. 
z = 1.284 
p>0.05=N.S. 
z = 3.283 
p<0.01=H.S. 
z = 4.780 
p<0.001=H.S. 
 
Table 6: Effect of Therapy on Pain
Group Grading Pain Intra group 
comparison  BT Follow up1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
 
0 0 0 0 0 0 0 6 33.3 2 = 37.084 
p = 0.000 
(p<0.001 HS) 
1 6 33.3 7 38.9 3 16.7 10 55.6 
2 7 38.9 9 50 8 44.4 2 11.1 
3 5 27.8 2 11.1 6 33.3 0 0 
4 0 0 0 0 1 5.6 0 0 
 
B 
(n=17) 
0 0 0 0 0 0 0 3 17.6 2 = 21.130 
p = 0.000 
(p<0.001 HS) 
1 6 35.3 8 47.1 8 47.1 8 47.1 
2 7 41.2 6 35.3 6 35.3 6 35.3 
3 4 23.5 3 17.6 3 17.6 0 0 
4 0 0 0 0 0 0 0 0 
Pairwise 
group 
comparison  
A Vs C z= 0.465 
p= 0.642 
z= 0.398 
p= 0.691 
z= 1.647 
p= 0.100 
z= 1.661 
p= 0.097 
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Table 7: Effect of Therapy on Swelling
Group Grading Swelling Intra group 
comparison  BT Follow up 1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 0 0 0 0 2 11.1 6 33.3 2 = 29.040 
p = 0.000 
(p<0.001 = H.S.) 
1 6 33.3 10 55.6 9 50 9 50 
2 12 66.7 8 44.4 7 38.9 3 16.7 
3 0 0 0 0 0 0 0 0 
 
B 
(n=17) 
0 1 5.9 1 5.9 0 0 0 0 2 = 4.784 
p = 0.188 
(P>0.05 = N.S.) 
1 7 41.2 5 29.4 4 23.5 5 29.4 
2 9 52.9 11 64.7 13 76.5 12 70.6 
3 0 0 0 0 0 0  0 0 
Pairwise 
group 
comparison  
A Vs B z = 0.925 
p>0.05=N.S 
z = 0.983 
p>0.05=N.S 
z = 2.324 
p<0.05=S. 
z = 3.941 
p<0.001=H.S. 
 
Table 8: Effect of Therapy on Stiffness
Group Grading Stiffness Intragroup 
comparison 
(Friedman’s test) 
BT Follow up 1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 0 0 0 0 0 0 5 27.8 2 = 34.408 
p = 0.000 
(p<0.001 = H.S.) 
1 6 33.3 6 33.3 12 66.7 12 66.7 
2 12 66.7 12 66.7 6 33.3 1 5.6 
3 0 0 0 0 0 0 0 0 
 
B 
(n=17) 
0 3 17.6 3 17.6 2 11.8 1 5.9 2 = 4.714 
p = 0.194 
(p>0.05 = N.S.) 
1 3 17.6 3 17.6 4 23.5 4 23.5 
2 11 64.7 11 64.7 10 58.8 9 52.9 
3 0 0 0 0 1 5.9 3 17.6 
Pairwise 
group 
comparison  
 
A Vs B 
z = 1.046 
p>0.05=N.S 
z = 1.046 
p>0.05=N.S. 
z = 2.597 
P<0.05=S. 
z = 4.245 
P<0.001=H.S. 
 
Table 9: Effect of Therapy on Walking Time
Group Grading Walking Time Index Intragroup 
comparison  BT Follow up 1 Follow up 2 Follow up 3 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 1 5.6 1 5.6 1 5.6 5 27.8 2 = 32.486 
p = 0.000 
(p<0.001 =H.S.) 
1 5 27.8 6 33.3 10 55.6 11 61.1 
2 7 38.9 11 61.1 7 38.9 2 11.1 
3 5 27.8 0 0 0 0 0 0 
 
B 
(n=17) 
0 0 0 0 0 0 0 0 0 2 = 4.400 
p = 0.221 
(p>0.05 = N.S.) 
1 4 23.5 4 23.5 4 23.5 3 17.6 
2 9 52.9 11 64.7 11 64.7 9 52.9 
3 4 23.6 2 11.8 2 11.8 5 29.4 
Pairwise 
group 
comparison  
 
A VsB 
z = 0.465 
p>0.05=N.S. 
z = 1.341 
p>0.05=N.S. 
z = 2.402 
p<0.05=S. 
z = 4.206 
p<0.001=H.
S 
 
Table 10: Effect of Therapy on Grip Power
Group Grading Grip Power Intragroup 
comparison 
(Friedman’s test) 
Right Arm Left Arm 
BT AT AT BT 
No. % No. % No. % No. % 
 
A 
(n=18) 
0 2 11.1 4 22.2 2 11.1 5 27.8 Rt X2 = 12.000 
 p = 0.001 
Lt X2 = 12.000 
 p = 0.001 
1 4 22.2 8 44.4 4 22.2 6 33.3 
2 7 38.9 5 27.8 7 38.9 6 33.3 
3 5 27.8 1 5.6 5 27.8 1 5.6 
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B 
(n=17) 
0 2 11.8 2 11.8 2 11.8 2 11.8 Rt X2 = 4.000 
 p = 0.046 
Lt X2 = 3.000 
 p = 0.083 
1 4 23.5 2 11.8 3 17.6 2 11.8 
2 8 47.1 8 47.1 9 52.9 8 47.1 
3 3 17.6 5 29.4 3 17.6 5 29.4 
Pairwise 
group 
comparison  
A Vs B z = 0.465 
p = 0.642 
z = 3.398 
p = 0.001 
z = 0.465 
p = 0.642 
z = 3.219 
p = 0.001 
 
Table 11: Effect of Therapy on Pressing Power 
Group Grading Press Power Intragroup 
comparison 
(Friedman’s 
test) 
Right Arm Left Arm 
BT AT AT BT 
No. % No. % No. % No. % 
A 
(n=18) 
0 2 11.1 4 22.2 2 11.1 5 27.8 Rt X2 = 11.000 
 p = 0.001 
Lt X2 = 11.000 
 p = 0.001 
1 5 27.8 8 44.4 5 27.8 6 33.3 
2 6 33.3 5 27.8 6 33.3 6 33.3 
3 5 27.8 1 5.6 5 27.8 1 5.6 
 
B 
(n=17) 
0 0 0 0 0 1 5.9 0 0 Rt X2 = 4.000 
 p = 0.046 
Lt X2 = 5.000 
 p = 0.025 
1 5 29.4 3 17.6 4 23.5 3 17.6 
2 8 47.1 8 47.1 8 47.1 8 47.1 
3 4 23.5 6 35.3 4 23.5 6 35.3 
Pairwise 
group 
comparison  
A Vs B z = 0.465 
p = 0.642 
z = 3.398 
p = 0.001 
z = 0.465 
p = 0.642 
z = 3.219 
p = 0.001 
 
 According to laboratory findings, the 
reduction in R.A. factor, CRP titre and ESR level 
was highly significant in group A after completion 
of therapy. In group B, this was highly significant 
only in ESR levels. There was significant rise in 
Hb% in patients of group A. 
 
Table 12: Effect of Therapy on Blood Components 
Components Group BT AT BT ~ AT Intragroup 
comparison paired 
t test BT Vs AT 
Intergroup 
comparison A 
Vs B 
RA factor  A 87.95± 78.14 21.65± 15.62 66.30± 76.20 3.89 p<0.01 HS t=2.39, p<0.01 
B 41.50± 21.35 41.13± 27.63 0.3750±20.89 0.961 p>0.05 NS 
CRP titre A 6.65± 5.67 1.73± 1.29 4.915± 4.84 4.54 p<0.001HS t=4.00, p<0.001 
B 3.68± 2.39 4.90± 5.62 1.22± 4.9 1.06 p>0.05 NS 
Hb% A 11.99± 1.33 12.29± 1.17 0.305± 0.383 3.56 p<0.01 HS t=3.63, p<0.05 
B 10.65± 1.40 10.98± 1.40 0.325± 0.498 1.08 p>0.05 NS 
ESR A 48.55± 10.20 29.40± 7.40 19.15± 10.97 7.80 p<0.001HS t=5.53, p<0.01 
B 34.00± 9.01 38.75± 11.56 4.75± 8.34 1.61 p>0.151 HS 
 There was neither any side effect 
produced nor any side effect observed during the 
trial drug therapy, though in standard group of 
Indomethacin, some patients developed complaint 
of GI upset, acidity and burning sensation in 
epigastrium 
DISCUSSION 
 Amavata affects the Sandhi (joints) and 
Hridaya Marma (heart)[1], which form a part of 
Madhyama Roga Marga[5]. Though Ama and Vata 
are the chief pathogenic factors, the disease 
represents the vitiation of Tridosa (humours)[6]. 
The affliction of Sandhi [of which Asthi (bones) is a 
component] by Vata and association with Ama, 
reflects the role of homogenous Dosa (humours) 
and Dusya (TulyaDosa Dusya) in the causation of 
this disease. Moreover, the chief pathogenic 
factors i.e. Ama and Vata being contradictory in 
character, pose difficulty in planning the line of 
treatment. Mandagni is a prerequisite factor for 
the initiation of the Samprapti (pathogenesis) of 
Amavata. 
To understand the probable mode of 
action of the drug, first of all we should consider 
the related basic fundamental principles of action 
of a drug, which are described in the classics. 
I. The conjugation of Rasas (Rasa Sannipata) 
etc. their mutual subordination and variation 
in processing (Vikalpanair-Vikalpitanama) on 
the basis of Prakriti Samasamavaya and 
Vikriti Vishamasamavaya[7]  theories are to be 
analyzed to decide the total effect (Samudaya 
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Prabhava) of the drug on the Doshas (or 
disease). It is because the active ingredients 
in a compound formulation show either 
antagonism (Parasparena Cha Upahatanam) 
or synergism (Abhivardhana) effects[8] 
II. The drugs are active due to their own 
inherent constituents (Dravya Prabhava), 
properties (Guna Prabhava) and both 
combined (Dravyaguna Prabhava) together in 
particular time, on reaching particular site, 
with a particular mechanism and objective[9] 
III. The different properties of a drug are 
inferred by observing their effects on the 
body[10] 
When seen as combination, most of the 
constituents are of Katu Tikta Rasa, Katu Vipaka, 
Ushna Veerya and Kaphavatashamaka. They are 
Deepana, Pachana, Laghu, Sukshma, Teekshna[11] 
and Rasona, which is the main ingredient, is an 
important Rasayana (rejuvenation)[12]. So, the 
drug Rasona Pinda also inherits these properties. 
Hence due to Rasa Veerya and Vipaka, it 
has Deepana action, which acts upon the major 
factor in Samprapti, i.e. Agnimandya. 
As it is Laghu, Sukshma and Teekshna, it 
can enter even Sukshma Srotasa (minute 
channels) and helps to remove Ama out of Srotasa 
and clear them for smooth functioning of Vata. So, 
Srotorodhajanita Vataprakopa is pacified. 
The Vishyandana action of Lavana and 
Chedana action of Kshara in the combination adds 
to this by removal of Ama that is stuck (Leena) in 
Srotasa.  
Most of the drugs of this combination are 
Kaphavatashamaka. Vata vitiated due to its own 
Nidana (etiology) is pacified. Kaphashamaka 
property is helpful when we think about the 
Adhishthana of the disease, i.e. Shleshmasthana. It 
is also helpful in condition where there is 
dominance of Kapha. Thus overall the drug helps 
in Samprapti Vighatana (breaking the 
pathogenesis) of the disease and is helpful in the 
condition. 
CONCLUSION 
The present trial was done to provide a 
drug for Rheumatoid Arthritis which is effective, 
yet cheaper, easy to be administered and has 
minimum side effects. The study revealed that 
trial formulation Rasona Pinda is effective in the 
management or more precisely, cure of Amavata 
vis-à-vis Rheumatoid Arthritis. 
The specific Ayurvedic line of management 
and drugs helps in decreasing the autoantigens 
and may act to modify the immune response to 
autoantigens. At the same time the drug is safe 
and can be given for longer duration without any 
adverse effect. Thus it can be concluded that this 
drug proves to be a better alternative for the 
conventional therapy prescribed for Rheumatoid 
Arthritis. 
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